Search clinical trials for: Glucagon receptor antagonist

Total 41625 results

Ali Aminian

Not yet recruiting

Fibrosis Lessens After Metabolic Surgery (FLAMES)

Obesity | Liver Fibrosis | Non-Alcoholic Fatty Liver Disease | Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) | Metabolic Dysfunction-Associated Steatohepatitis (MASH)

United States, Sweden, Ireland, Finland, United Kingdom, Spain, Switzerland, Brazil, Canada, Italy, Kuwait, India, Mexico
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Not yet recruiting

Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery

Delirium, Postoperative
RenJi Hospital

Recruiting

Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney Disease

Obesity | Chronic Kidney Diseases

China
Christopher D. Verrico

Recruiting

Exenatide For Reducing the Reinforcing Effects of Cocaine

Cocaine Use Disorder

United States
Novo Nordisk A/S

Recruiting

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

Type 2 Diabetes

United States, Taiwan, Australia, Hungary, Germany, India, Canada, Spain, Czechia, Argentina, Poland, Colombia, South Africa, France, Greece, Romania
University of Chicago

Not yet recruiting

Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues

Multiple Sclerosis | Obesity | Obesity, Morbid | Obese | Long COVID | Long Covid19 | Acute Leukemia in Remission
University of Missouri-Columbia
American Society for Metabolic and Bariatric Surgery

Recruiting

Impact GLP-1 Agonists Following Bariatric

Hypertension | Diabetes Mellitus | Metabolic Syndrome | Morbid Obesity | Obstructive Sleep Apnea of Adult

United States
Novo Nordisk A/S

Recruiting

A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

Obesity

United States
Washington University School of Medicine
Novo Nordisk A/S

Not yet recruiting

Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia

Endometrial Hyperplasia

United States
Wuhan Union Hospital, China
Peking University First Hospital

Recruiting

High Risk Population of Cardiovascular Disease in Hubei Province Screening and Intervention Program

Cardiovascular Diseases | Coronary Disease | Diabetes Mellitus, Type 2

China
RenJi Hospital

Recruiting

Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Obesity, Abdominal | Non-Alcoholic Fatty Liver Disease | Metabolism Disorder, Glucose | Metabolism Disorder, Lipid | Metformin | Abdominal Fat

China
Louisiana State University Health Sciences Center...
Tulane University; Pennington Biomedical Research Center; Ochsner Health System

Recruiting

Anti-obesity Pharmacotherapy and Inflammation

Obesity

United States
AstraZeneca

Not yet recruiting

A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs (EXCEED)

Pancreatic Cancer
Maisa N. Feghali, MD

Recruiting

Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes

Gestational Diabetes

United States
The Affiliated Nanjing Drum Tower Hospital of Nanjing...
Nanjing First Hospital, Nanjing Medical University; Wuxi People's Hospital; Changzhou... and other collaborators

Recruiting

Effects of Liraglutide, Empagliflozin and Linagliptin on the Cognitive Function in T2DM Patients With Mild Cognitive Impairment: a Multicenter, Randomized, Parallel Controlled Clinical Trial

Type 2 Diabetes Mellitus | Mild Cognitive Impairment

China
Mansoura University

Recruiting

Endoscopic Ultrasound Guided Gastric Botulinum Toxin Injections Versus Glucagon Like Peptide 1 Receptor Agonist in Weight Loss

Obesity

Egypt
Filip Krag Knop

Recruiting

The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients With Type 2 Diabetes

Obesity | Type 2 Diabetes

Denmark
The Affiliated Hospital of Xuzhou Medical University

Recruiting

Effect of Gene Polymorphisms on GLP-1 Receptor Agonists Response in Patients With T2DM

Type 2 Diabetes Mellitus

China
Second Xiangya Hospital of Central South University
Guangdong Provincial People's Hospital; The First Affiliated Hospital of Henan... and other collaborators

Recruiting

The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.

Diabetes Mellitus, Type 2 | Overweight or Obesity

China
Fundació Institut de Recerca de l'Hospital de la...
Instituto de Salud Carlos III

Recruiting

Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)

Pituitary Diseases | Hypothalamic Diseases | Hypopituitarism | Social Isolation | Panhypopituitarism | Psychological Disorder | Central Diabetes Insipidus | Oxytocin Deficiency

Spain
Duke University
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Recruiting

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) (POPS or POP02)

Heart Failure | Pain | Pneumonia | Hypertension | Edema | Hemophilia | Insomnia | Pulmonary Arterial Hypertension | Coagulation Disorder | Asthma in Children | Down Syndrome | Attention Deficit Hyperactivity Disorder | Bronchopulmonary Dysplasia | Hypokalemia | Hyperphosphatemia | Primary Hyperaldosteronism | Adrenal Insufficiency and other conditions

United States, Canada
University of Miami
Novo Nordisk A/S

Recruiting

Liraglutide Effects on Epicardial Fat Inflammatory Genes

Coronary Artery Disease | Type2 Diabetes

United States
Christina Kruuse

Recruiting

The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Stroke (EGRABIS1)

Ischemic Stroke

Denmark
Camillo Ricordi and Jay Skyler
Diabetes Research Institute Foundation

Not yet recruiting

Diabetes Islet Preservation Immune Treatment (DIPIT)

Autoimmune Diseases | Diabetes Mellitus | Hypoglycemia | Diabetes Mellitus, Type 1

United States
Eli Lilly and Company

Completed

A Study of Tirzepatide in Overweight and Very Overweight Participants

Obesity | Overweight

United States
Radboud University Medical Center

Completed

Imaging Pituitary ActiVation by Exendin (iPAVE)

Diabetes Mellitus, Type 2

Netherlands
Eunice Kennedy Shriver National Institute of Child...

Completed

Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve Gastrectomy

Obesity | Status Post Sleeve Gastrectomy

United States
Novo Nordisk A/S

Enrolling by invitation

Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.

Obesity

Taiwan
Bayer

Active, not recruiting

An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice (FINEGUST)

Type 2 Diabetes Mellitus | Chronic Kidney Disease

Japan, Spain, Netherlands, United Kingdom, Denmark, United States
Seattle Children's Hospital
University of Washington

Active, not recruiting

Brain Activation and Satiety in Children 2 (BASIC2)

Childhood Obesity

United States
University Hospital, Basel, Switzerland
Gottfried und Julia Bangerter-Rhyner-Stiftung

Completed

Exenatide-test for Diagnosing Endogenous Hyperinsulinemic Hypoglycemia (FAST)

Endogenous Hyperinsulinism

Switzerland
Eli Lilly and Company

Active, not recruiting

A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CVOT)

Type 2 Diabetes Mellitus

China, United States, Netherlands, Spain, Australia, Austria, India, Canada, Taiwan, United Kingdom, Belgium, France, Germany, Mexico, Romania, Italy, Argentina, Brazil, Puerto Rico, Ukraine, Hungary, Japan, Czechia, Turkey, Korea, Republic... and more
Novo Nordisk A/S

Active, not recruiting

SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity

Obesity

United States, Belgium, Malaysia, Portugal, Russian Federation, Switzerland, India, Israel, Mexico
Eli Lilly and Company

Active, not recruiting

A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) (SURPASS-SWITCH)

Type 2 Diabetes

United States, Belgium, Germany, Mexico, Romania
University at Buffalo
AstraZeneca

Terminated

GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes (1981)

Kidney Diseases | Type2 Diabetes

United States
Eli Lilly and Company

Active, not recruiting

A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both (SURPASS-PEDS)

Glucose Metabolism Disorders | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Endocrine System Diseases | Type2 Diabetes | Metabolic Disease | T2DM (Type 2 Diabetes Mellitus) | T2D

United States, India, Australia, United Kingdom, Mexico, Brazil, Israel, France, Italy
CorEvitas
Eli Lilly and Company

Withdrawn

The Purpose of This Registry Study is to Learn More About Metabolic Health: Approximately 15,000 Participants Who Are Overweight or Have Obesity With or Without Metabolic Diseases Are Expected to Participate in This Registry Study.

Metabolic Health
Novo Nordisk A/S

Completed

A Research Study Looking at Long-term Blood Sugar Control in People With Type 2 Diabetes Being Treated With Xultophy® in a Real-world Setting in Italy

Diabetes Mellitus, Type 2

Italy
Qianfoshan Hospital

Active, not recruiting

Therapeutic Drug Use for CKD Patients

Chronic Kidney Disease

China
Cambridge University Hospitals NHS Foundation Trust

Completed

Haemodynamic Effects of GLP-1 and Glucagon in Healthy Male Volunteers (COCOA)

Cardiovascular Diseases

United Kingdom
University of Miami

Active, not recruiting

Liraglutide Effect in Atrial Fibrillation (LEAF)

Atrial Fibrillation

United States
Lindner Center of HOPE

Completed

Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)

Obesity | Bipolar Disorder

United States
Mayo Clinic
Novo Nordisk A/S

Active, not recruiting

Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy

Obesity

United States
Cedars-Sinai Medical Center
Novo Nordisk A/S; The Cure Parkinson's Trust

Completed

Safety and Efficacy of Liraglutide in Parkinson's Disease

Parkinson Disease

United States
Eli Lilly and Company

Active, not recruiting

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities (SURMOUNT-5)

Obesity | Overweight

United States, Puerto Rico
Milton S. Hershey Medical Center
National Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)

Completed

Use of a GLP-1R Agonist to Treat Opioid Use Disorder

Opioid-Related Disorders | Opiate Substitution Treatment

United States
Hospital de Clinicas de Porto Alegre

Completed

The Use of Liraglutide in Brain Death

Brain Death

Brazil
The University of Texas Health Science Center at...

Suspended

Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM

Type 2 Diabetes | Insulin Sensitivity | Glucose Tolerance Impaired

United States
Boehringer Ingelheim

Completed

A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes

Diabetes Mellitus, Type 2

Denmark
Eli Lilly and Company

Completed

A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)

Type 2 Diabetes

United States, Puerto Rico, Spain, Germany, Argentina, Brazil, Turkey, Hungary, Italy, Russian Federation, Slovakia, Belgium, Czechia, Greece, Mexico, Romania

Search clinical trials for: Glucagon receptor antagonist

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations